-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $47

Benzinga·01/21/2026 14:43:05
Listen to the news
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.